+65 3158 9940
1300 798 820
+64 9801 0299
Melbourne, January 2014 – A leading breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival (OS) for patients with metastatic pancreatic cancer when used in combination with current standard of care, gemcitabine, with some patients surviving longer than three years.1 The updated OS data from the pivotal Phase III Metastatic Pancreatic Adenocarcinoma
Melbourne, June 2013 Melbourne biopharmaceutical company Specialised Therapeutics Australia has become the first corporate sponsor of an international charitable organisation which enables medical and surgical specialists to impart their expertise to colleagues in developing countries. The company has become the inaugural donor for the Specialists Without Borders (SWB) organisation, an Australian based non-profit entity established in
Melbourne, November 2012 Specialised Therapeutics Australia (STA) is pleased to announce that the phase III, randomised, international study of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival. This is now the fourth disease in which ABRAXANE has demonstrated positive phase III results,
Melbourne, Australia May 2012: Patients with an aggressive form of brain tumour, glioblastoma multiforme (GBM), have been given access to a new brain tumour visualisation drug, Gliolan® (5-aminolevulinic acid), at The Royal Melbourne Hospital. In 2011, The Royal Melbourne Hospital trialled the drug with great success, and is expected to treat up to an additional 25
CANCER DRUG ABRAXANE® IN FOCUS AT INTERNATIONAL CONFERENCE Delegates to hear trial results for future possible ABRAXANE indications including lung cancer and melanoma Melbourne: 27 May 2010: World leading advanced breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) will be in focus at a leading international medical conference in Chicago next week. Specialised Therapeutics Australia Pty Ltd (STA), which